A Cure for Cancer Might Be on the Way -- and It Could Turn Healthcare Investing Upside DownThe Motley Fool • 01/31/20
Novartis AG (NVS) CEO Vasant Narasimhan on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 01/29/20
Novartis Edges Higher Into Buy Zone Even As Generic Drugs StruggleInvestors Business Daily • 01/29/20
Swiss pharmaceutical giant warns finding a coronavirus vaccine will take 'over a year'CNBC • 01/29/20
Novartis Starts 2020 a Step Ahead of Other Big Pharmas with the Most Newly Approved DrugsThe Motley Fool • 01/15/20
AbbVie and Boehringer Ingelheim's Skyrizi Beat Novartis' Cosentyx in Plaque PsoriasisThe Motley Fool • 01/14/20
Novartis' Heart Drug Gets Accelerated Review in Britain for High-Risk PatientsThe Motley Fool • 01/13/20